Nephrogenic epistaxis.
Kumar R, Sikka K, Kumar R, Chatterjee P.
Singapore Med J. 2014 Jul;55(7):e112-3. doi: 10.11622/smedj.2013185.
Metastatic renal cell carcinoma risk according to tumor size.
Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, Bernstein M, Coleman J, Dalbagni G, Touijer K, Russo P.
J Urol. 2009 Jul;182(1):41-5. doi: 10.1016/j.juro.2009.02.128. Epub 2009 May 17.
[Gemcitabine-induced thrombotic microangiopathy].
Teixeira L, Debourdeau P, Zammit C, Estival JL, Pavic M, Colle B.
Presse Med. 2002 Apr 27;31(16):740-2.
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.
Murphy KA, James BR, Guan Y, Torry DS, Wilber A, Griffith TS.
Hum Vaccin Immunother. 2015;11(7):1612-20. doi: 10.1080/21645515.2015.1035849.
Systemic Therapy for Metastatic Renal-Cell Carcinoma.
Choueiri TK, Motzer RJ.
N Engl J Med. 2017 Jan 26;376(4):354-366. doi: 10.1056/NEJMra1601333.
Follow-up Management of Cystectomy Patients.
Reddy M, Kader K.
Urol Clin North Am. 2018 May;45(2):241-247. doi: 10.1016/j.ucl.2018.01.001.
Tumor-to-tumor metastasis of the central nervous system.
Erdogan H, Aydin MV, Tasdemiroglu E.
Turk Neurosurg. 2014;24(2):151-62. doi: 10.5137/1019-5149.JTN.8317-13.1.
Cadherins in renal cell carcinoma.
Heicappell R.
Anticancer Res. 1999 Mar-Apr;19(2C):1501-4.
Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database.
Lee CH, Kang M, Kwak C, Ko YH, Kim JK, Park JY, Bang S, Seo SI, Suh J, Song W, Song C, Lee HH, Chung J, Jeong CW, Jo JK, Choi SH, Choi J, Choi C, Choo SH, Han JH, Hong SH, Hwang EC.
J Korean Med Sci. 2024 Nov 25;39(45):e293. doi: 10.3346/jkms.2024.39.e293.
[Metastatic renal failure].
Cluzel P, Enache I, Roche-Lachaise I, Justrabo E.
Nephrol Ther. 2006 Feb;2(1):41-6. doi: 10.1016/j.nephro.2005.08.006. Epub 2005 Nov 8.
